Clinical trial
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
NCT00049296 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00049296 |
|---|---|
| Title | Thalidomide and Docetaxel in Treating Patients With Advanced Cancer |
| Official title | Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on Anti-Angiogenic Therapeutic Principles |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, thalidomide |
| Enrollment | 26 |
| Start date | Jul 1, 2002 |
| Primary completion | Dec 1, 2004 |
| Completion | Jan 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 11, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: